Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

Qilu Hospital of Shandong University64 enrolled

Overview

The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).

Portal vein thrombosis (PVT) is a frequent complication of liver cirrhosis, referred to partial or complete thrombosis formed in the lumen of portal vein or/and branches of it. Currently, clinical guidelines of PVT in cirrhotic patients has not been addressed, and anticoagulant therapy of PVT patients with cirrhosis remains controversial. Although numerable studies have reported that anticoagulation therapy is effective, while a majority of them were respective and a few took control into consideration. In addition, no agreement has reached about the safety of anticoagulation. So, the efficacy and safety of anticoagulant therapy needs more prospective randomized controlled trial to be investigated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Liver Cirrhosis Portal Vein Thrombosis

Interventions

Nadroparin calcium, warfarinDRUG

Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 18 and 75 years * Liver cirrhosis diagnosis based on clinical, laboratory, and imaging studies, and PVT diagnosed by abdominal contrast-enhanced computed tomography, contrast-enhanced MRI, or portal angiography Exclusion Criteria: * Cavernous transformation of the portal vein * Uncontrolled active bleeding * Platelet count lower than 10\*10\^9/L * Creatinine more than 170 mmol/L * Ongoing or received antithrombotic/thrombolytic treatment * Primary thrombophilia * Budd-Chiari syndrome * Pregnancy or breast-feeding period * Severe cardiopulmonary diseases * Severe systemic infection or sepsis * Inability to sign informed consent

Locations (1)

Department of Gastroenterology,Qilu Hospital,Shandong University

Jinan, Shandong, China

Outcomes

Primary Outcomes

Recanalization Rate

For each venous segment, the vein and residual patent lumen were outlined at the level of the maximum thrombosis. Total lumen area and patent lumen area were calculated with commercially available software. The degree of thrombus occlusion was estimated as a percentage by thrombosis area/total lumen area×100%. The primary outcome was the overall recanalization rate, both complete and partial. Complete recanalization was referred to the complete disappearance of the thrombus in the portal vein trunk, at least one of the two intrahepatic portal vein branches, SMV and SV. Partial recanalization was defined as a more than 50% reduction of the thrombus, with the thrombus not extending to other veins.

Time frame: 6 months

Secondary Outcomes

Rate of Bleeding

Risk of bleeding episodes

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.